258 related articles for article (PubMed ID: 28566625)
1. Effective-Loading of Platinum-Chloroquine into PEGylated Neutral and Cationic Liposomes as a Drug Delivery System for Resistant Malaria Parasites.
Ibrahim S; Tagami T; Ozeki T
Biol Pharm Bull; 2017; 40(6):815-823. PubMed ID: 28566625
[TBL] [Abstract][Full Text] [Related]
2. Interactions of primaquine and chloroquine with PEGylated phosphatidylcholine liposomes.
Miatmoko A; Nurjannah I; Nehru NF; Rosita N; Hendradi E; Sari R; Ekowati J
Sci Rep; 2021 Jun; 11(1):12420. PubMed ID: 34127730
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of chloroquine-loaded and heparin surface-functionalized solid lipid nanoparticles.
Muga JO; Gathirwa JW; Tukulula M; Jura WGZO
Malar J; 2018 Apr; 17(1):133. PubMed ID: 29606144
[TBL] [Abstract][Full Text] [Related]
4. Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy.
Moles E; Urbán P; Jiménez-Díaz MB; Viera-Morilla S; Angulo-Barturen I; Busquets MA; Fernàndez-Busquets X
J Control Release; 2015 Jul; 210():217-29. PubMed ID: 26008752
[TBL] [Abstract][Full Text] [Related]
5. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method.
Qiu L; Jing N; Jin Y
Int J Pharm; 2008 Sep; 361(1-2):56-63. PubMed ID: 18573626
[TBL] [Abstract][Full Text] [Related]
6. Optimisation of chloroquine phosphate loaded nanostructured lipid carriers using Box-Behnken design and its antimalarial efficacy.
Baruah UK; Gowthamarajan K; Ravisankar V; Karri VVSR; Simhadri PK; Singh V
J Drug Target; 2018 Aug; 26(7):576-591. PubMed ID: 29057679
[TBL] [Abstract][Full Text] [Related]
7. PEGylated peptide dendrimeric carriers for the delivery of antimalarial drug chloroquine phosphate.
Bhadra D; Bhadra S; Jain NK
Pharm Res; 2006 Mar; 23(3):623-33. PubMed ID: 16374532
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
[TBL] [Abstract][Full Text] [Related]
9. New drug candidates for liposomal delivery identified by computer modeling of liposomes' remote loading and leakage.
Cern A; Marcus D; Tropsha A; Barenholz Y; Goldblum A
J Control Release; 2017 Apr; 252():18-27. PubMed ID: 28215669
[TBL] [Abstract][Full Text] [Related]
10. ImmunoPEGliposomes for the targeted delivery of novel lipophilic drugs to red blood cells in a falciparum malaria murine model.
Moles E; Galiano S; Gomes A; Quiliano M; Teixeira C; Aldana I; Gomes P; Fernàndez-Busquets X
Biomaterials; 2017 Nov; 145():178-191. PubMed ID: 28869864
[TBL] [Abstract][Full Text] [Related]
11. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
12. Long circulatory liposomal maduramicin inhibits the growth of Plasmodium falciparum blood stages in culture and cures murine models of experimental malaria.
Raza M; Bharti H; Singal A; Nag A; Ghosh PC
Nanoscale; 2018 Jul; 10(28):13773-13791. PubMed ID: 29995025
[TBL] [Abstract][Full Text] [Related]
13. A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro.
Urbán P; Estelrich J; Cortés A; Fernàndez-Busquets X
J Control Release; 2011 Apr; 151(2):202-11. PubMed ID: 21223986
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes.
Buyens K; Demeester J; De Smedt SS; Sanders NN
Langmuir; 2009 May; 25(9):4886-91. PubMed ID: 19341292
[TBL] [Abstract][Full Text] [Related]
15. Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior.
Mohammadi ZA; Aghamiri SF; Zarrabi A; Talaie MR
Curr Drug Deliv; 2016; 13(7):1065-1070. PubMed ID: 26708673
[TBL] [Abstract][Full Text] [Related]
16. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
17. Persistence of chloroquine-resistant haplotypes of Plasmodium falciparum in children with uncomplicated Malaria in Lagos, Nigeria, four years after change of chloroquine as first-line antimalarial medicine.
Oladipo OO; Wellington OA; Sutherland CJ
Diagn Pathol; 2015 Apr; 10():41. PubMed ID: 25928117
[TBL] [Abstract][Full Text] [Related]
18. Nanocomposite liposomes containing quantum dots and anticancer drugs for bioimaging and therapeutic delivery: a comparison of cationic, PEGylated and deformable liposomes.
Wen CJ; Sung CT; Aljuffali IA; Huang YJ; Fang JY
Nanotechnology; 2013 Aug; 24(32):325101. PubMed ID: 23867977
[TBL] [Abstract][Full Text] [Related]
19. Development of risperidone liposomes for brain targeting through intranasal route.
Narayan R; Singh M; Ranjan O; Nayak Y; Garg S; Shavi GV; Nayak UY
Life Sci; 2016 Oct; 163():38-45. PubMed ID: 27593571
[TBL] [Abstract][Full Text] [Related]
20. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
